SR One related stories
All articles and analysis
Data spotlight: U.K.-based companies raised nearly €339 mln in FebruaryFrance leads all European countries, with 28 companies in the country during the month
Spero Therapeutics nets $30 mln Series BCambridge, Massachusetts-based Spero Therapeutics, a biopharmaceutical company targeting drug resistant bacterial infections, raised $30 million in Series B preferred financing, matching the $30 million Series A round Spero raised in June. Existing Series A investors Atlas Venture, SR One, MRL Ventures, Lundbeckfond Ventures, The Kraft Group and Partners Innovation Fund all returned to participated.
- Mission Therapeutics raises $85.8 mln
Mission Therapeutics said Tuesday it raised a 60 million pound ($85.8 million) financing round led by Imperial Innovations Businesses LLP. New investor Woodford Patient Capital Trust Plc took part with follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments. U.K.-based Mission Therapeutics is a drug discovery and development company.
- eFFECTOR Therapeutics nabs $40 mln Series B
San Diego-based eFFECTOR Therapeutics, a biopharmaceutical company focused on treating cancer, has raised $40 million in Series B funding. The investors were Altitude Life Science Ventures, AbbVie Biotech Ventures, BioMed Ventures, Abingworth, Novartis Venture Fund, SR One, The Column Group, US Venture Partners, Astellas Ventures, Osage University Partners and Mission Bay Capital. In addition to the funding, eFFECTOR has named Dave Maki, managing partner of Altitude Life Science Ventures, to its board of directors.
- Brace Pharma Capital leads $33 mln Series B funding in Navitor
Brace Pharma Capital led a $33 million Series B funding in Navitor Pharmaceuticals, a biopharmaceutical company. Other investors in the funding included Remeditex Ventures, Sanofi-Genzyme BioVentures and an undisclosed individual investor. Existing investors Polaris Partners, Atlas Venture, Johnson & Johnson Innovation and SR One also participated. Vinzenz Ploerer, president and chief executive officer of Brace Pharma Capital, will join Navitor's board.
- True North raises $40 mln
True North Therapeutics said Thursday that it completed a $40 million Series C equity financing led by New Leaf Venture Partners. Also participating were Perceptive Advisors and Cowen Private Investments, as well as existing investors Kleiner Perkins Caufield & Byers, MPM Capital, OrbiMed, SR One and Baxalta Ventures. San Francisco-based True North is a clinical stage biotechnology company.
- Hearing company Decibel Therapeutics nabs $52 mln Series A
Cambridge, Massachusetts-based hearing company Decibel Therapeutics has launched with $52 million in Series A funding. Third Rock Ventures LLC led the round with participation from SR One. In addition to the funding, Kevin Starr, chairman and interim CEO of Decibel Therapeutics, Craig Muir, partner and chief technology officer at Third Rock and Dr. Jens Eckstein, president of SR One, have been named to Decibel Therapeutics' board of directors.
- Forbion Capital invests in Sanifit's $41 mln round
Sanifit raised 36.6 million Euros (US$41 million) in a Series C round of financing. Forbion Capital Partners took part in the round as well as Ysios Capital, Lundbeckfond Ventures, Gilde Healthcare, Edmond de Rothschild Investment Partners, “la Caixa” and Baxter Healthcare. Existing shareholders also supported the series C round. Sanifit is a Spanish clinical-stage biopharmaceutical company.
- RaNA Therapeutics snaps up $55 mln
Cambridge, Massachusetts-based RaNA Therapeutics, a RNA-focused drug developer, has closed $55 million in Series B funding. MRL Ventures and the Baupost Group LLC led the round with participation from other investors that included Rock Springs Capital Management, Brookside Capital, Leerink Partners LLC, Atlas Venture, Monsanto, MS Ventures, Omega Funds, Partners Innovation Fund, Pfizer Venture Investments and SR One. In addition to the funding, Dr. Joshua Resnick, president of MRL Ventures, has been added to RaNA's board of directors.
Gladius Pharmaceuticals nets $4.1 mln in Series A led by Lumira CapitalGladius Pharmaceuticals Inc has secured $4.1 million in a Series A financing. The round was led by Canadian venture capital firm Lumira Capital through its Merck Lumira Biosciences Funds. Joining Lumira in the deal was the Fonds de solidarité FTQ and SR One, an affiliate of GlaxoSmithKline. Based in Montréal, Gladius is a biotechnology company focused on developing novel drugs to treat life-threatening, multi-drug-resistant bacterial infections. It is led by CEO Michael Atkin. Lumira's Daniel Hétu said the Gladius technology "is demonstrating strong promise to restore treatment options for resistant Gram-negative infections which have become a global challenge."